Company Encyclopedia
View More
name
JYPC
002198.SZ
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablets (capsules), Shufeng Huoluo tablets, Tiaomeng Huoxue tablets, etc.
3.159 T
002198.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking66/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.45%C
    • Profit Margin9.64%B
    • Gross Margin43.50%B
  • Growth ScoreC
    • Revenue YoY-1.35%D
    • Net Profit YoY221.73%A
    • Total Assets YoY-2.67%D
    • Net Assets YoY-4.25%D
  • Cash ScoreC
    • Cash Flow Margin1037.12%B
    • OCF YoY-1.35%D
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreA
    • Gearing Ratio8.48%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    JYPC: Completed the repurchase of 0.1970% to 2.048% of the company's shares

    JYPC held a board meeting on December 12, 2024, to approve a share repurchase plan, intending to repurchase 7 million to 13.5 million shares, with an amount not exceeding 132 million yuan. As of October 9, 2025, 10.396 million shares have been repurchased, accounting for 2.048% of the total share capital. The highest transaction price was 7.04 yuan/share, the lowest was 5.96 yuan/share, with a total amount of 69.9872 million yuan

    Zhitong·
    SZ
    002198
    -1.49%
    Zhitong·
    SZ
    002198
    -1.49%

    JYPC: Net profit in the first half of the year was 20.0826 million yuan, a year-on-year increase of 254.33%

    On the evening of August 25th, JYPC disclosed its 2025 semi-annual report, showing an operating income of 199 million yuan in the first half of the year, a year-on-year increase of 10.4%; net profit attributable to the parent company was 20.0826 million yuan, a year-on-year increase of 254.33%; basic earnings per share were 0.0396 yuan

    Zhitong·
    SZ
    002198
    -1.49%
    Zhitong·
    SZ
    002198
    -1.49%

    JYPC signed a technology development contract with Hunan University of Traditional Chinese Medicine

    JYPC's wholly-owned subsidiary signed a technology development contract with Hunan University of Traditional Chinese Medicine to develop the innovative traditional Chinese medicine "Juanbi Lijie Qing Granules." In the contract, Hunan University of Traditional Chinese Medicine provides the traditional Chinese medicine prescription and technical support, while JYPC is responsible for pharmaceutical research, pharmacological and toxicological research, and clinical research, with the ultimate goal of obtaining the drug clinical trial approval notice

    Zhitong·
    SZ
    002198
    -1.49%
    Zhitong·
    SZ
    002198
    -1.49%

    JYPC's Chief Financial Officer Shi Junping resigns

    According to the Zhitong Finance APP, JYPC announced that the company's board of directors recently received a written resignation letter submitted by Mr. Shi Junping, the company's Chief Financial Officer. Mr. Shi resigned from his position as Chief Financial Officer for personal reasons. According to relevant regulations, his resignation will take effect from the date it is delivered to the board of directors, and he will no longer hold any position in the company after his resignation, which will not affect the normal operation of the company

    Zhitong·
    SZ
    002198
    -1.49%
    Zhitong·
    SZ
    002198
    -1.49%

    JYPC: The disclosure date for the Q1 2025 report has been moved up to April 25

    JYPC announced that the company was originally scheduled to disclose the first quarter report of 2025 on April 30, 2025. After applying to and receiving approval from the Shenzhen Stock Exchange, the disclosure date has been changed to April 25, 2025. The company's first quarter report of 2025 will be disclosed on April 25, 2025, on the Giant Tide Information Network, Securities Times, China Securities Journal, and Securities Daily. Investors are advised to pay attention to the announcement

    Zhitong·
    SZ
    002198
    -1.49%
    Zhitong·
    SZ
    002198
    -1.49%
    © 2025 Longbridge｜Disclaimer